Rational drug design based mainly on the pathobiochemistry of the disease: Examples of atheromatosis and alzheimer’s type neurodegeneration

Chemistry and Molecular Aspects of Drug Design and Action

Volumn , Issue , 2008, Pages xv-xxii

  Rekka, Eleni A ^a   Kourounakis, A P ^b   Kourounakis, Panos N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056026490     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420008272     Document Type: Editorial

References (29)

1. Christofferson, R.E. and Marr, J.J., The management of drug discovery. In Burger’s Medicinal Chemistry and Drug Discovery. Vol 1: Principles and practice. Wolf, A., Ed., Wiley Interscience, New York, 1995, pp. 9-36.
2. Chrysselis, M.C., Rekka, E.A., and Kourounakis, P.N., Antioxidant therapy and cardiovascular disorders, Exp. Opin. Ther. Patents, 11, 33, 2001.
3. Chrysselis, M.C., Rekka, E.A., and Kourounakis, P.N., Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity, J. Med. Chem., 43, 609, 2000.
4. Berliner, J.A. et al., Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics, Circulation, 91, 2488, 1995.
5. Pannala, A.S. et al., Interaction of peroxynitrite with carotenoids and tocopherols within low density lipoprotein, FEBS Lett., 423, 297, 1998.
6. Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s, Nature, 362, 801, 1993.
7. McMurray, H.F. et al., Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes, J. Clin. Invest., 1004, 1993.
8. Ku, G. et al., Induction of interleukin 1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid, J. Biol. Chem., 267, 14183, 1992.
9. Eberhardt, R.T. and Loscalzo, J., Nitric oxide in atherosclerosis. In Nitric Oxide and the Cardiovascular System. Loscalzo, J. and Vita, J.A., Eds., Humana Press, New Jersey, 2000, pp. 273-295.
10. Rekka, E. and Kourounakis, P.N., Synthesis, physicochemical properties and biological studies of some substituted 2-alkoxy-4-methyl-morpholines, Eur. J. Med. Chem., 24, 179, 1989.
11. Rekka, E. et al., Lipophilicity of some substituted morpholine derivatives synthesized as potential antinociceptive agents, Arch. Pharm., 323, 53, 1989.
12. Hadjipetrou-Kourounakis, L. et al., Immunosuppression by a novel analgesic-opioid agonist, Scand. J. Immunol., 29, 449, 1989.
13. Tani, E. et al., Modification of drug metabolic processes by compounds which intervene with the function of cytochrome P-450 as a mono-oxygenase and as an oxidase, Arzneim.-Forsch./Drug Res., 39, 1399, 1989.
14. Brown, G.R. et al., Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors, J. Med. Chem., 39, 2971 1996.
15. Chrysselis, M.C. et al., Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents, J. Med. Chem., 45, 5406, 2002.
16. Tavridou, A. et al., Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis, Eur. J. Pharmacol., 535, 34, 2006.
17. Tavridou, A. et al., EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit, J. Pharmacol. Exp. Ther., 323, 794, 2007.
18. Praticò, D., Oxidative imbalance and lipid peroxidation in Alzheimer’s disease, Drug Dev. Res., 56, 446, 2002.
19. Davis, K.L. and Samuels, S.C., Dementia and delirium. In Pharmacological Management of Neurological and Psychiatric Disorders. Enna, S.J. and Coyle, J.T., Eds., McGraw Hill, Columbus, OH, 1998, pp. 267-316.
20. Michaelis, M.L., Drugs targeting Alzheimer’s disease: some things old and some things new, J. Pharmacol. Exp. Ther., 304, 897, 2003.
21. Kourounakis, A. and Bodor, N., Quantitative structure activity relationships of catechol derivatives on nerve growth factor secretion in L-M cells, Pharm. Res., 12, 1199, 1995.
22. Gudasheva, T.A. et al., Design of N-acylprolyltyrosine “tripeptoid” analogues of neurotensin as potential atypical antipsychotic agents, Eur. J. Med. Chem., 31, 151, 1996.
23. Romanova, G.A. et al., Antiamnesic effect of acyl-prolyl-containing dipeptide (GVS-111) in compression-induced damage to frontal cortex, Bull. Exp. Biol. Med., 130, 846, 2000.
24. Steiner, J.P. et al., Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models, Proc. Natl. Acad. Sci. U.S.A., 94, 2019, 1997.
25. Steiner, J.P. et al., Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A, Nat. Med., 3, 421, 1997.
26. Kourounakis, P.N. et al., Reduction of gastrointestinal toxicity of NSAIDs via molecular modifications leading to antioxidant anti-inflammatory drugs, Toxicology, 144, 205, 2000.
27. Galanakis, D. et al., Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity, Bioorg. Med. Chem. Lett., 14, 3639, 2004.
28. Doulgkeris C.M. et al., Synthesis and pharmacochemical study of novel polyfunctional molecules combining anti-inflammatory, antioxidant, and hypocholesterolemic properties, Bioorg. Med. Chem. Lett., 16, 825, 2006.
29. Siskou, I.C. et al., Design and study of some novel ibuprofen derivatives with potential nootropic and neuroprotective properties, Bioorg. Med, Chem., 15, 951, 2007.